Tampere Epilepsy Research Group

VNS does more than reduce seizures in drug-resistant #epilepsy: A new study led by professor Jukka Peltola reveals patients with depressive symptoms may have even better seizure control with #VNS! 🧠⚡ sciencedirect.com/science/articl… @Epilepsialiitto @SuomenNeuro @NeurocenterFI

Professor Jukka Peltola delivering his talk @KuopioEpilepsy symposium on “home monitoring possibilities of epileptic seizures” @rkalviainen @Tre_Brain_Mind @NeurocenterFI #KES2024 @neuroeventlabs

Participating virtually @KuopioEpilepsy @rkalviainen

@KuopioEpilepsy When do virtual participants receive the link to join the event ?

💡Navigating the Complex World of Epilepsy Comorbidities: Expert Insights! onlinelibrary.wiley.com/doi/abs/10.100… offers practical, evidence-based advice to empower neurologists in the care of patients with epilepsy @jukka_nekujupe @NeurocenterFI @Tre_Brain_Mind @Epilepsialiitto @Tays_sairaala

Peltola et al. present results from MORE registry supporting the effectiveness and safety of ANT-DBS therapy in a real-world setting, including drug-resistant focal epilepsy patients from 25 centers and 13 countries @jukka_nekujupe @Medtronic n.neurology.org/content/early/…

Our results not only provides additional pathophysiologic significance of IL-6 but also offers a new possibility of therapeutic intervention, in the treatment of GADA-induced autoimmune epilepsy, read more frontiersin.org/articles/10.33… @jukka_nekujupe @NeurocenterFI @Tre_Brain_Mind

Lectio precursia: Erittäin aktiivisen aaltomaisen MS-taudin lääkehoitojen turvallisuus. Väittelijä: Ilkka Rauma Vastaväittäjä: dosentti Eero Rissanen, @UniEastFinland Kustos: Professori Jukka Peltola, @TampereUni #tamperebrainandmind #codedtoconnect @NeurocenterFI

In an interview at the 14th European Epilepsy Congress 2022 in Geneva, Prof. Peltola shares insights on the use of ANT-DBS in patients with drug-resistant epilepsy @jukka_nekujupe @NeurocenterFI @Tre_Brain_Mind @Epilepsialiitto youtube.com/watch?v=l0V47z…

.@jukka_nekujupe @TampEpilep @Tre_Brain_Mind presents new outcome results of deep brain stimulation treatment in epilepsy on last day of #eec2022 @IlaeWeb

Home videos can improve #epilepsy care and management. Our study confirms the clinical utility of seizure monitoring system #Nelli® at patients' home. Read more at sciencedirect.com/science/articl… @NeurocenterFI @Tre_Brain_Mind @Tays_sairaala @TampereUni @TampereUniMET @neuroeventlabs

Interesting case report on the positive effects of VNS on controlling the “cytokine storm” associated with COVID-19. #COVID19 ncbi.nlm.nih.gov/pmc/articles/P…

Prof. Jukka Peltola: Tärkein tavoitteemme on saada kaikki tutkijat ja yritykset, jotka ovat tekemisissä aivotutkimuksen kanssa - laajasti ajateltuna - yhteistyöhön ja etsimään synergiaetuja Tampereella ja koko Suomessa #codedtoconnect @TampereUni @Tays_sairaala @jukka_nekujupe

Combined AI and human expertise, without EEG, for reviewing nocturnal video recordings significantly decreases the workload and provides accurate classification of major motor seizures in Epilepsy @neuroeventlabs @NeurocenterFI @Epilepsialiitto onlinelibrary.wiley.com/doi/10.1111/ep…

What #neuromodulation devices will neurologists in 2035 have access to? Read the latest article in the #Neurology Future Forecasting Series to learn more: bit.ly/3nijjGj

A single-centre follow-up study of 263 epilepsy patients (2009-2018) @Tays_sairaala reports exciting results on treatment outcomes in women with idiopathic generalized epilepsy: highlighting valproate and its alternatives. onlinelibrary.wiley.com/doi/full/10.11… @jukka_nekujupe @NeurocenterFI

COVID‐19 vaccine take‐up rate and safety in adults with epilepsy: Data from a multicenter study in China onlinelibrary.wiley.com/doi/10.1111/ep…